This week, the U.S. Patent and Trademark Office (USPTO) issued a memorandum introducing new processes related to discretionary denials of...

This morning, in a likely pro-patent holder approach, the U.S. Patent and Trademark Office (USPTO) rescinded a guidance memorandum from...

A biosimilar is a biologic drug that is highly similar, but not identical, to an already approved biologic drug, i.e. the reference...